使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and thank you for standing by. Welcome to GE Healthcare's second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I will hand the call over to the Chief Investor Relations Officer, Carolynne Borders. You may begin.
各位大家好,感謝您耐心等候。歡迎參加 GE Healthcare 2024 年第二季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。我將把電話交給投資人關係長 Carolynne Borders。您可以開始了。
Carolynne Borders - IR
Carolynne Borders - IR
Thanks, operator. Good morning, and welcome to GE Healthcare's second-quarter 2024 earnings call. I'm joined by our President and CEO, Peter Arduini; and Vice President and CFO, Jay Saccaro.
謝謝,接線員。各位早安,歡迎參加 GE Healthcare 2024 年第二季財報電話會議。今天與我一同出席的有我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Jay Saccaro。
Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website.
我們在本次電話會議中的發言將同時包含 GAAP 與非 GAAP 財務結果。GAAP 與非 GAAP 指標之間的調節表可在今日新聞稿以及我們網站上的簡報投影片中找到。
During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. And with that, I'll hand the call over to Peter.
在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前對情勢的看法。如我們向 SEC 提交的文件所述,實際結果可能因風險與不確定性而出現重大差異。接下來,我把電話交給 Peter。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Thanks, Carolynne, and thanks to all those joining us today. In the second quarter, we delivered 1% organic revenue and 3% orders growth with all segments contributing. We also expanded margins despite headwinds in the China market.
謝謝你,Carolynne,也感謝今天加入我們的各位。第二季,我們實現了 1% 的有機營收成長與 3% 的訂單成長,且所有事業部門皆有貢獻。儘管中國市場面臨逆風,我們仍擴大了利潤率。
We saw particular strength in the US given replacement cycles and increased use of imaging across disease stage for diagnostics, and resilience in the ultrasound market. Excluding China, global revenue growth was 4%, and orders growth was 6%. We believe we're gaining market share in each of our segments, and we are continuing to invest in products and services that will accelerate growth in the future.
我們在美國市場看到特別強勁的表現,受惠於汰換週期,以及影像檢查在各疾病階段診斷用途的增加;同時超音波市場也展現韌性。若排除中國,全球營收成長為 4%,訂單成長為 6%。我們相信在各個事業部門都正在提升市占率,並持續投資於產品與服務,以加速未來成長。
As it relates to China performance, we previously communicated that the region would experience negative sales growth in the first half as we face a challenging compare. At the time, we expected positive sales growth in the second half.
就中國的表現而言,我們先前已溝通,由於比較基期具挑戰性,該地區在上半年將出現負的銷售成長。當時我們預期下半年銷售成長將轉為正值。
Today, the prolonged timing of the rollout of the new stimulus announced earlier this year is impacting timing of orders and sales. We expect a continued sales decline in China year over year in the second half, and we anticipate growth in China will be negative for the year. As a result, we're lowering our total company full year organic revenue growth guidance.
今天,由於今年稍早宣布的新刺激措施推行時程延後且時間拉長,正影響訂單與銷售的時點。我們預期中國在下半年仍將呈現年對年銷售下滑,並預估中國全年成長將為負值。因此,我們下調公司全年有機營收成長指引。
It's important to note that despite this revenue reduction, we are maintaining our EPS guidance for the year. Although, we're disappointed with the second half reduction in sales growth, this is a temporary challenge, and we expect to see China market orders recovery later in the year. We continue to view this market as an attractive long-term opportunity.
需要強調的是,儘管營收預期下修,我們仍維持全年 EPS 指引不變。雖然我們對下半年銷售成長下修感到失望,但這是暫時性的挑戰,我們預期今年稍晚中國市場訂單將回升。我們仍將此市場視為具吸引力的長期機會。
While China weighed on orders and revenues were encouraged by our margin performance in the quarter, our team has embraced lean and identified process and product improvements at the end of 2023 and the first half of 2024. We're now seeing those benefits coming through our P&L along with increased customer satisfaction, ultimately resulting in higher win rates in products and services.
儘管中國拖累訂單與營收,我們對本季的利潤率表現感到鼓舞;我們的團隊已採行精實(lean)方法,並在 2023 年底及 2024 年上半年辨識出流程與產品改善項目。我們現在正看到這些效益反映在損益表上,同時客戶滿意度提升,最終帶來產品與服務更高的得標率。
We're making great progress executing improvements that deliver better value to our customers and patients and eliminating waste, leveraging continuous improvement or kaizen. We run approximately 400 sessions throughout the year, and recently completed our global CEO Kaizen Week. During the week, we held 28 events across our sites where my leadership team and I joined colleagues to drive and execute process changes and improvements, which is a key aspect of a good kaizen.
我們在執行改善方面取得重大進展,透過持續改善(continuous improvement)或改善活動(kaizen),為客戶與病患提供更佳價值並消除浪費。我們全年約進行 400 場活動,並且最近完成了全球 CEO Kaizen Week。在那一週,我們在各據點共舉辦 28 場活動,我與領導團隊加入同仁,一同推動並落實流程變更與改善,這是良好 kaizen 的關鍵面向。
Teams were focused on growth, cost, and working capital improvements, some of which have immediate impact at the end of the week, while others will drive impact later in the year. One of our cost improvement kaizens, a team consisting of engineering, quality, and sourcing build a plan for a high running CT platform that will reduce overall costs by 23%, with 15% coming out in the first year.
各團隊聚焦於成長、成本與營運資金改善,其中部分在週末即產生立即影響,另一些則將在今年稍晚帶來效益。在其中一項成本改善 kaizen 中,由工程、品質與採購組成的團隊為一個高運轉的 CT 平台制定計畫,將整體成本降低 23%,其中 15% 將在第一年實現。
In Waukesha, my team focused on improving our responsiveness to customer demand as well as cost savings for the CT and PET/CT products that we manufacture there. We create a visual management tool called Heijunka board that shows plant capacity, system availability, and customer orders.
在 Waukesha,我的團隊聚焦於提升我們對客戶需求的回應速度,以及我們在當地製造的 CT 與 PET/CT 產品的成本節省。我們建立了一個稱為 Heijunka board 的視覺化管理工具,用以呈現工廠產能、系統可用性與客戶訂單。
The new tool will help us level load production, optimize manufacturing flow and meet customer demand while shrinking the lead time on our critical Omni Legend PET/CT system by 31%, and reduce future costs to create these scanners. It was an energizing week for all. Leveraging our productivity progress this year, we are raising our adjusted EBIT margin guidance, and we're reaffirming our outlook for adjusted EPS and free cash flow. Jay will discuss our outlook in greater detail later in the call.
這項新工具將協助我們平準化生產負荷、最佳化製造流程並滿足客戶需求,同時將關鍵的 Omni Legend PET/CT 系統交期縮短 31%,並降低未來製造這些掃描儀的成本。對所有人而言,那是一個令人振奮的一週。憑藉今年的生產力進展,我們上調調整後 EBIT 利潤率指引,並重申調整後 EPS 與自由現金流的展望。Jay 稍後將在電話會議中更詳細說明我們的展望。
Moving to commercial execution milestones. As I mentioned, we had a strong quarter in the US where we secured more than $800 million of multimodality equipment, software and service contracts. The US market continues to be robust, particularly in imaging, IGT and ultrasound. We saw strong orders and sales growth in the region and continue to see a healthy pipeline for growth.
接著談商業執行的里程碑。如我所提到的,我們在美國度過了強勁的一季,取得超過 8 億美元的多模態設備、軟體與服務合約。美國市場持續強勁,尤其是在影像、IGT 與超音波領域。我們在該地區看到強勁的訂單與銷售成長,並持續看到健康的成長管線。
In July, we made two important announcements to develop proprietary AI tools to help expedite clinical and operational efficiencies. This included our agreement to acquire the AI division of Intelligent Ultrasound, a developer of AI tools for women's health ultrasound products, and a strategic collaboration with Amazon Web Services to build foundation models and generative AI tools to streamline hospital operations and care delivery. Now, I'll pass it to Jay, who will take us through the details of our second quarter performance. Jay?
7 月,我們發布兩項重要公告,以開發專有的 AI 工具,協助加速臨床與營運效率。其中包括我們同意收購 Intelligent Ultrasound 的 AI 事業部(其為女性健康超音波產品 AI 工具的開發商),以及與 Amazon Web Services 的策略合作,共同建立基礎模型與生成式 AI 工具,以簡化醫院營運與照護交付流程。接下來我把電話交給 Jay,由他帶我們了解第二季表現的細節。Jay?
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Thanks, Pete. Let's start with our financial performance on slide 4. For the second quarter of 2024, revenues of $4.8 billion were up 1% organically year over year. Recall this quarter's results compared to 9% growth in the second quarter of 2023, when we experienced easing supply chain constraints.
謝謝你,Pete。我們先從第 4 張投影片的財務表現開始。2024 年第二季,營收為 48 億美元,有機年對年成長 1%。請回想,本季結果是與 2023 年第二季的 9% 成長相比;當時我們正經歷供應鏈限制的緩解。
As you can see from our filing this morning, the continued market headwinds in China impacted total company sales growth in the quarter by approximately 300 basis points, meaning, global sales growth excluding China was approximately 4%.
如您從我們今早的申報文件所見,中國市場持續的逆風使本季公司整體銷售成長約減少 300 個基點;也就是說,若排除中國,全球銷售成長約為 4%。
Organic orders growth was solid increasing 3% year over year, driven by strength in the US and rest of world. Excluding a 300-basis point impact of China on orders, orders growth would have been 6%. Orders dollars continue to outpace sales leading to a strong total company book to bill of 1.06 times versus 1.04 times last year. As a reminder, equipment only book to bill is higher than total company book to bill. We exited the second quarter with a healthy backlog of $19 billion including strong services growth.
有機訂單成長穩健,年對年增加 3%,主要由美國及其他地區的強勁表現帶動。若排除中國對訂單造成的 300 個基點影響,訂單成長將為 6%。訂單金額持續快於銷售,使公司整體出貨比(book to bill)達 1.06 倍,優於去年的 1.04 倍。提醒一下,僅設備的出貨比高於公司整體出貨比。第二季結束時,我們的在手訂單(backlog)維持健康水準,達 190 億美元,其中包含強勁的服務成長。
Adjusted EBIT margin was 15.3%, up 60 basis points year over year, driven by continued improvement in gross margin with productivity and price. Second-quarter adjusted EPS was $1, up 9% year over year, reflecting adjusted EBIT growth and lower interest expense. Free cash flow was in line with our expectations and was negative due to the timing of certain payments.
調整後 EBIT 利潤率為 15.3%,年對年提升 60 個基點,主要受惠於生產力與定價帶動的毛利率持續改善。第二季調整後 EPS 為 1 美元,年對年成長 9%,反映調整後 EBIT 成長以及利息費用降低。自由現金流符合我們的預期,因部分付款時點因素而為負值。
On slide 5, let's take a closer look at segment revenue performance for the second quarter. We saw very strong PDx sales growth of 14% organically, aligned to global procedural demand. China market headwinds negatively impacted both our imaging and ultrasound segments. Service revenue on a reported basis increased 2%.
在第 5 張投影片上,讓我們更深入檢視第二季各事業部的營收表現。我們看到 PDx 銷售有機成長 14%,表現非常強勁,與全球手術量需求一致。中國市場逆風對我們的影像與超音波兩個事業部均造成負面影響。以報告基礎計算,服務營收成長 2%。
We continue to make very good progress on margin expansion. Let's walk through this on slide 6. In the quarter, adjusted gross margin expanded 110 basis points, and adjusted EBIT margin expanded 60 basis points.
我們在毛利率擴張方面持續取得非常良好的進展。讓我們在第 6 張投影片上逐步說明。本季調整後毛利率擴張 110 個基點,調整後 EBIT 利潤率擴張 60 個基點。
The team has made significant progress, utilizing lean capabilities to focus on margin accretive actions. As a result of these actions, adjusted gross margin increased 100 basis -- 110 basis points and adjusted EBIT margin grew 60 basis points through the first half of 2024.
團隊已取得顯著進展,運用精實能力聚焦於提升利潤率的行動。在這些行動帶動下,2024 年上半年調整後毛利率提升 100 個基點——110 個基點,調整後 EBIT 利潤率成長 60 個基點。
Gross margin was particularly strong in PDx with volume and stabilization of raw material costs, and Imaging gross margin expanded, led by new product introductions. In our PDx segment, we hosted a kaizen in our court facility in May, which led to over 1.5 million doses of annual capacity improvement and cycle time reduction. This is another great example of how lean enables us to increase our volume and expand margins.
PDx 的毛利率表現特別強勁,受惠於出貨量提升以及原物料成本趨於穩定;影像事業部毛利率亦擴張,主要由新產品導入帶動。在 PDx 事業部,我們於 5 月在法院設施(court facility)舉辦了一場改善活動(kaizen),使年度產能提升超過 150 萬劑,並縮短週期時間。這是精實如何協助我們提升產量並擴大利潤率的另一個絕佳例子。
In IT, we're focused on permanent cost optimization actions that are resulting in ongoing cost savings. For example, we have consolidated more than 40 vendors supporting our applications to one vendor, as we signed a managed service agreement that has resulted in more than $40 million of annual savings.
在 IT 方面,我們聚焦於永久性的成本最佳化行動,並帶來持續性的成本節省。例如,我們已將支援應用程式的 40 多家供應商整併為 1 家供應商,並簽署託管服務協議,帶來每年超過 4,000 萬美元的節省。
As we exit TSAs, we're developing solutions specific to GE HealthCare's needs. For example, moving more to the cloud and reducing internal data centers, as well as consolidating the number of devices we use. We expect this to drive an additional $20 million of savings in 2024.
隨著我們退出 TSA(過渡服務協議),我們正在開發更符合 GE HealthCare 需求的解決方案。例如,更多遷移至雲端並縮減內部資料中心,同時整併我們使用的裝置數量。我們預期這將在 2024 年帶來額外 2,000 萬美元的節省。
On the gross profit side, we drove mid-single digit variable cost productivity across all segments in the quarter. In the second quarter, we invested more than $300 million in R&D, growing 10% year over year, while expanding our margin. Recently introduced products with AI are driving higher margins.
在毛利端,本季我們在所有事業部推動了中個位數的變動成本生產力提升。第二季我們在研發上投資超過 3 億美元,年增 10%,同時仍擴大利潤率。近期導入 AI 的新產品正帶動更高的利潤率。
Now, I'll turn to segment performance. Let's start with imaging on slide 7, where we had flat organic revenue growth. This was against a difficult comparison to the prior year when sales were up 9%. Growth in this segment was also impacted by China market headwinds.
接下來我將說明各事業部表現。先從第 7 張投影片的影像事業部開始,我們的有機營收成長持平。這是在與去年銷售成長 9% 的高基期相比之下的結果。該事業部的成長也受到中國市場逆風影響。
Segment EBIT margin was up 40 basis points year over year. We continue to make progress on enhancing gross margins through productivity and price, while also investing in R&D. Margin improved sequentially by 130 basis points versus the first quarter of 2024 due to volume leverage. New product introductions are contributing to particular strength in US product demand.
事業部 EBIT 利潤率年增 40 個基點。我們持續透過生產力提升與定價來改善毛利率,同時也持續投資研發。由於量能槓桿,利潤率較 2024 年第一季環比改善 130 個基點。新產品導入正帶動美國市場產品需求的特別強勁表現。
Turning to ultrasound on slide 8. Organic revenue was down 1% year over year, primarily due to China market headwinds. Segment EBIT margin decreased 120 basis points year over year, driven by lower sales in China and inflation. This was partially offset by cost productivity achieved through standardization and new product introductions. We continue to see solid customer demand, especially for our recently launched products.
接著看第 8 張投影片的超音波事業部。有機營收年減 1%,主要因中國市場逆風所致。事業部 EBIT 利潤率年減 120 個基點,主要受中國銷售下滑與通膨影響。部分影響由透過標準化與新產品導入所達成的成本生產力所抵銷。我們仍看到穩健的客戶需求,尤其是對我們近期推出的產品。
Moving to patient care solutions on slide 9. Organic revenue was up 1% year over year, following 9% growth in the prior year. Segment EBIT margin decreased 90 basis points year over year due to product mix, while productivity actions offset inflation with expected contributions from new product introductions and a healthy backlog, we are well positioned to drive future growth.
接著看第 9 張投影片的病患照護解決方案。有機營收年增 1%,此前一年為成長 9%。事業部 EBIT 利潤率年減 90 個基點,主因為產品組合;同時,生產力行動抵銷了通膨。隨著新產品導入的預期貢獻以及健康的在手訂單,我們具備推動未來成長的良好條件。
Moving to pharmaceutical diagnostics on slide 10. We had another strong quarter, generating 14% year-over-year organic growth, driven by volume, pricing, and new product introductions. Segment EBIT margin of 31.2% improved 450 basis points year over year driven by sales volume, productivity and pricing. We're pleased with the continued margin expansion in this segment
接著看第 10 張投影片的藥物診斷(PDx)。我們再度交出強勁的一季,有機成長年增 14%,由出貨量、定價與新產品導入所帶動。事業部 EBIT 利潤率為 31.2%,年增 450 個基點,主要受銷售量、生產力與定價帶動。我們對該事業部持續的利潤率擴張感到滿意。
Security of supply remains top of mind for our customers, and we're continuing to make investments to enhance global supply of contrast agents and radiopharmaceuticals to meet increased demand. In particular, we're encouraged by positive developments in the molecular imaging market. We saw continued acceleration of Vizamyl doses delivered in the US in the second quarter. These sales increased three-fold.
供應安全仍是客戶最關注的重點之一,我們持續投資以提升造影劑與放射性藥物的全球供應,以滿足增加的需求。尤其是,我們對分子影像市場的正向發展感到鼓舞。第二季我們看到在美國交付的 Vizamyl 劑量持續加速成長。這些銷售成長了三倍。
Turning to slide 11 on cash flow performance. In the second quarter, free cash flow was negative, $182 million due to the normal timing of compensation and interest payments. We continue to expect strong cash generation for the full year. Free cash flow is expected to be substantially higher in the second half of the year relative to the first as a result of seasonality, given higher volumes as well as the timing of certain supplier and compensation payments that occur earlier in the year. Our strong cash flow profile continues to provide us the flexibility to advance our growth strategy, while reinvesting in the business and executing a disciplined capital allocation strategy.
接著看第 11 張投影片的現金流表現。第二季自由現金流為負 1.82 億美元,主要因薪酬與利息支付的正常時點所致。我們仍預期全年將有強勁的現金創造能力。由於季節性因素(包括更高的出貨量),以及部分供應商與薪酬付款在年初發生的時點影響,我們預期下半年自由現金流將顯著高於上半年。我們強勁的現金流特性持續提供彈性,使我們能推進成長策略,同時再投資於業務並執行嚴謹的資本配置策略。
Now, let's turn to our outlook on slide 12. We're taking a prudent approach and are lowering our full-year 2024 organic revenue growth guidance to be in the range of 1% to 2% due to temporary market headwinds in China. Despite this reduction, we're raising our guidance for adjusted EBIT margin expansion, which we now expect to be 60 to 90 basis points year over year, associated with the continued momentum we're seeing on productivity and optimization initiatives, along with contribution from NPIs.
現在,讓我們看第 12 張投影片的展望。我們採取審慎作法,因中國暫時性的市場逆風,將 2024 全年有機營收成長指引下調至 1% 至 2% 的區間。儘管下調營收指引,我們上調調整後 EBIT 利潤率擴張指引;目前預期年增 60 至 90 個基點,反映我們在生產力與最佳化計畫上的持續動能,以及新產品導入(NPI)的貢獻。
We're reaffirming our expected -- our expectation for adjusted EPS in the range of $4.20 to $4.35 with growth of 7% to 11% and free cash flow of approximately $1.8 billion. We expect third quarter year-over-year organic revenue growth of approximately 1% and adjusted EBIT margin expansion to be relatively similar to second quarter.
我們重申——我們對調整後 EPS 的預期為 4.20 至 4.35 美元區間,成長 7% 至 11%,自由現金流約 18 億美元。我們預期第三季有機營收年增約 1%,調整後 EBIT 利潤率擴張將與第二季大致相近。
We would expect year over-year-organic revenue growth and adjusted EBIT margin in the fourth quarter to be the highest of the year. As you think about the year, I would note that we expect the revenue headwind from foreign exchange to be less than 1% in 2024. Now, I'd like to turn the call back over to Pete.
我們預期第四季的有機營收年增與調整後 EBIT 利潤率將是全年最高。就全年而言,我想補充說明,我們預期 2024 年外匯對營收的逆風將低於 1%。現在,我想把電話會議交回給 Pete。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Thanks, Jay. Building on my comments from earlier in the call, our lean culture has allowed us to create a strong pipeline of innovation and accelerate our ability to bring differentiated solutions to market for patients and customers. We'll dive deeper into some of what you see on the slide at Investor Day. But today, I'd like to focus on growth in PDx and imaging.
謝謝,Jay。延續我在先前電話會議中的評論,我們的精實文化使我們得以建立強大的創新管線,並加速將差異化解決方案推向市場,以服務病患與客戶。我們會在投資人日更深入探討投影片上所呈現的一些內容。但今天,我想聚焦於 PDx 與影像的成長。
We're encouraged by the recent CMS reimbursement proposal and has potential to benefit patients in the US who are facing cancer, cardiovascular and neurological diseases. This step is expected to unlock the value of our radiopharmaceuticals, and PET, and SPECT scanners, ultimately enabling more precise diagnostic and treatment planning for patients.
我們對近期 CMS 的給付提案感到鼓舞,該提案有潛力讓美國面臨癌症、心血管與神經系統疾病的病患受益。此舉預期將釋放我們放射性藥物,以及 PET 與 SPECT 掃描儀的價值,最終使病患能進行更精準的診斷與治療規劃。
To give you some perspective, for the last decade, these molecular imaging agents were treated as a supply with limited reimbursement with prevented broad scale use. Assuming the new rule goes into effect on January 1, 2025, we expect CMS will begin paying market value for these agents, some of which have an average sale price of thousands of dollars.
為了讓各位更有概念,過去十年,這些分子影像造影劑一直被視為給付受限的供應項目,有限的償付也阻礙了其大規模使用。假設新規則於2025年1月1日生效,我們預期CMS將開始以市場價值支付這些造影劑,其中部分產品的平均銷售價格高達數千美元。
The change will give hospitals the needed reimbursement to cover their costs better, which has been a long-standing challenge in this space. This comes at a time when we continue to see momentum with existing radiopharmaceuticals, including DaTscan, Vizamyl and Cerianna and the promise of future molecules such as flurpiridaz, for cardiovascular disease. We expect each of these products will benefit from the new reimbursement rule.
這項變更將使醫院獲得所需的償付,以更好地涵蓋其成本,而這一直是此領域長期存在的挑戰。同時,我們也持續看到既有放射性藥物的動能,包括DaTscan、Vizamyl與Cerianna,以及用於心血管疾病的未來分子(如flurpiridaz)所帶來的前景。我們預期這些產品都將受惠於新的償付規則。
As Jay mentioned, Vizamyl doses continued to grow in the second quarter in the US with the recent FDA approval of donanemab. We anticipate even further uptick of our diagnostic amyloid PET agent. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years.
如Jay所提到,隨著donanemab近期獲得FDA核准,Vizamyl在美國第二季的使用劑量持續成長。我們預期我們的診斷用類澱粉蛋白PET造影劑將進一步上升。目前這仍是銷售成長中的小幅貢獻者,但讓我們對其未來幾年的銷售潛力感到樂觀。
On the equipment side of PET imaging, we expanded our upgradable Omni Legend platform by introducing a smaller detector providing upgradability and value, so customers can adopt the scanner to meet the evolving needs of their patients.
在PET影像設備方面,我們透過導入較小的偵測器來擴充可升級的Omni Legend平台,提供可升級性與價值,讓客戶能依病患需求的演進來調整掃描儀。
We also introduced MINItrace Magni, a small, low-cost cyclotron for in-house production of tracers and radioisotopes. And this will help regional hospitals with limited access to commercial distribution or larger hospitals with siting issues that prevent them from building the infrastructure needed to accommodate a traditional size cyclotron.
我們也推出MINItrace Magni,一款小型、低成本的迴旋加速器,可用於院內生產示蹤劑與放射性同位素。這將協助商業配送管道取得受限的區域型醫院,或因場址限制而無法建置傳統尺寸迴旋加速器所需基礎設施的大型醫院。
Turning to slide 14. We're aligning our ultrasound and image guided therapies business to better position ourselves for how clinicians use these two modalities in high growth settings. For example, you can see how multiple products work in conjunction inside an electrophysiology suite, and when integrated in the workflow, create a better experience for our customers and patients. These two businesses combined unlock more value than they do separately. We are looking forward to sharing more about this at Investor Day.
接著看第14頁投影片。我們正在調整超音波與影像導引治療業務的配置,以更好地因應臨床醫師在高成長場域中使用這兩種技術的方式。例如,各位可以看到多項產品如何在電生理手術室內協同運作,並在整合至工作流程後,為客戶與病患帶來更好的體驗。這兩項業務結合後所能釋放的價值,超過各自獨立運作時的總和。我們期待在投資人日分享更多內容。
We also made strategic leadership appointments aligned to these changes. As of July 1, Roland Rott, our previous Head of Ultrasound is leading imaging; and Phil Rackliffe, Head of Image Guided Therapies is leading ultrasound and IGT. Roland and Phil have deep industry knowledge, global mindset, and significant expertise with our products and operations, and they're well positioned to lead our two largest businesses and are off to a great start.
我們也配合這些變革進行策略性領導任命。自7月1日起,原超音波事業負責人Roland Rott將領導影像業務;而影像導引治療(IGT)事業負責人Phil Rackliffe將領導超音波與IGT。Roland與Phil具備深厚的產業知識、全球視野,以及對我們產品與營運的豐富專業,已準備好領導我們兩個最大的業務部門,且目前進展良好。
Before turning to Q&A on slide 15, I want to thank our team for their commitment to delivering for our customers. In particular, I'd like to thank our government affairs and policy team who advocated for multiple years the proposed CMS hospital outpatient rule for the benefit of patients.
在第15頁進入問答之前,我想感謝我們團隊致力於為客戶交付成果。特別是,我要感謝我們的政府事務與政策團隊,多年來持續倡議CMS醫院門診擬議規則,造福病患。
As I look ahead, I'm optimistic for a few reasons. One, we have a strong backlog at $19 billion. And with a prudent approach to our revenue guidance, we feel confident that we can deliver on our outlook. We're encouraged by overall capital equipment spend, particularly in the US We delivered solid orders growth in the quarter at 3% or 6% excluding China.
展望未來,我之所以樂觀有幾個原因。第一,我們有強勁的在手訂單,達190億美元。在對營收指引採取審慎作法的前提下,我們有信心能達成展望。我們也受到整體資本設備支出所鼓舞,尤其是在美國;本季訂單成長穩健,達3%,若排除中國則為6%。
Our funnel of productivity opportunities is strong, and we were able to raise our adjusted EBIT margin guidance due to our progress on these initiatives, and there's still much more to do here. We're excited about the pipeline of innovation. We have that solves customer challenges, enables improved patient care and sets us up well for growth in the years to come. More about this in November at our Investor Day. And lastly, given these factors, we're confident that we can deliver on our medium-term goals. With that, we'd like to open up for questions.
我們的生產力機會管道相當強勁,並且因這些計畫的進展,我們得以上調調整後EBIT利潤率指引,而在這方面仍有許多工作可做。我們對創新管線感到振奮。我們擁有能解決客戶挑戰、促進更佳病患照護並為未來數年成長奠定良好基礎的創新。更多內容將於11月的投資人日說明。最後,基於上述因素,我們有信心能達成中期目標。接下來我們開放提問。
Carolynne Borders - IR
Carolynne Borders - IR
Thank you, Peter. I'd like to ask participants to please limit yourself to one question and one follow-up. Operator, can you please open the line?
謝謝你,Peter。我想請與會者每人僅限一個問題與一個追問。接線員,請開放電話線路。
Operator
Operator
(Operator Instructions) Joanne Wuensch, Citi.
(接線員指示) Citi的Joanne Wuensch。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
Good morning and thank you for taking the question. I think I want to spend my question on China, and trying to understand how you think about the pace of opening up new orders from the stimulus program. When do you anticipate it arriving and how, as we put our 2025 models together, you think about this rolling into next year? Thank you.
早安,謝謝讓我提問。我想把問題聚焦在中國,並試著了解你們如何看待刺激方案帶動新訂單開放的速度。你們預期何時會到來?以及當我們建立2025年的模型時,你們如何看待這將如何滾入明年的表現?謝謝。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Hey, Joanne. It's Peter. Thanks for the question. So as I mentioned in my prepared remarks, the stimulus program rollout and the details of those plans are taking longer than we estimated, I think, than many people estimated. Just some background, in 2022, when there was a previous rollout just from the central government, it came out pretty quickly. I think it was around under six months from announcement to roll out. That was kind of the predicate we base assumptions on.
嗨,Joanne。我是Peter。謝謝你的問題。如我在事先準備的發言中提到,刺激方案的推出進度與計畫細節所花的時間比我們預估的更久,我想也比許多人預估的更久。補充一些背景:在2022年,先前僅由中央政府推動的一次推出,進展相當快。我記得從宣布到落地大約不到六個月。那是我們用來作為假設基礎的前例。
In '24, the rollout is taking longer, mainly because it's a combination of each of the 31 provinces and the central government working together and so that's taking longer to roll it out. And we believe that, that's going to be well into late '24 before it begins driving growth. So we've fundamentally taken that out of our numbers.
在2024年,推出時間拉長,主要是因為這次是31個省份與中央政府共同協作,因此推動落地需要更久。我們認為,要到2024年較晚的時候才會開始帶動成長。因此我們已在根本上把這部分從我們的數字中剔除。
We ultimately expect that this is going to be a positive catalyst for the China market. And we believe it could have a positive impact on orders starting in late '24. But we view this as a limited sales impact just on the time between tenders, orders, and sales to take place. And so taking it out of our numbers for the year, we viewed as prudent.
我們最終仍預期這將成為中國市場的正向催化劑。我們也相信它可能自2024年末開始對訂單產生正面影響。但就銷售而言,由於招標、下單到實際出貨認列之間存在時間差,我們認為其影響有限。因此,把它從今年的數字中拿掉,我們認為是審慎之舉。
But again, we would expect to see the benefit of stimulus having an impact in '25 and obviously, when it does come forward, we'll take advantage of it. Jay, you may want to add a few comments
不過再次強調,我們預期刺激方案的效益會在2025年反映出來;當然,一旦確實推進,我們也會把握機會。Jay,你或許可以補充幾點。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Yeah. Sure. Just a little more detail on this adjustment. When we provided guidance last quarter, we were estimating roughly a $50 million decline in sales in the second quarter. But we actually saw something worse than that. It was closer to $100 million.
好的。當然。我再補充一些關於這次調整的細節。我們在上季提供指引時,原本估計第二季銷售大約會下滑5,000萬美元。但實際看到的情況比那更差。更接近1億美元。
And so in fact, as we look at the first half of the year, you can see in our disclosures, trend is down about 15%. And we've assumed really as we look to the rest of the year, there's going to be no real impact from China stimulus sales.
因此,當我們看上半年時,各位可以在我們的揭露中看到,趨勢下滑約15%。而我們對今年剩餘期間的假設,基本上是中國刺激方案銷售不會帶來實質影響。
And also, we're kind of expecting a challenging market for the balance of the year. And so when you think about the guidance adjustment that we did as it relates to '24, at the midpoint of the range of the 1% to 2% range, it's roughly a $500 million impact in China relative to what we previously thought.
此外,我們也預期今年餘下時間市場仍將具挑戰性。因此,當你思考我們針對2024年所做的指引調整時,以1%到2%區間的中點來看,相較於我們先前的預期,中國部分的影響約為5億美元。
When China starts -- stimulus starts to come through, it will be a positive development. But we're not trying to time this or estimate the timing of the stimulus package, we've taken it out.
當中國的刺激方案開始逐步到位時,這會是正向發展。但我們不打算去押注或估算刺激方案的時間點,因此已將其從數字中剔除。
On the positive side, we do believe that we are well-positioned once stimulus starts coming through to take advantage of that, as Pete said. So overall, we think the market is a good long term attractive market.
從正面來看,我們確實相信,一旦刺激措施開始傳導落地,我們就已做好充分準備可以把握機會,如同 Pete 所說。因此整體而言,我們認為這個市場在長期來看是個具吸引力的優質市場。
But clearly, this year is challenging. The only thing I would say is, historically, China has been around -- or last year's roughly 14% of our business. It will be much less than that this year in the 11% to 12% range as we think about our current modeling.
但很明顯,今年充滿挑戰。我唯一想補充的是,從歷史來看,中國約占我們業務的——或者說去年大約占我們業務的 14%。依我們目前的模型推估,今年將遠低於此,約落在 11% 到 12% 的區間。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
Good morning. Thanks for taking the question. I wanted to start with the '24 guidance. Jay, as you mentioned, you lowered revenues by about $500 million. But maintain margins, actually increased margins a little bit and maintained EPS. So my question is, how are you able to maintain margins and EPS given the revenue reduction? I did have one follow-up.
早安。謝謝讓我提問。我想先從 2024 年的指引談起。Jay,如你提到的,你把營收下修了大約 5 億美元。但你維持了利潤率,甚至還略微提高利潤率,並且維持 EPS。所以我的問題是,在營收下修的情況下,你們如何仍能維持利潤率與 EPS?我還有一個追問。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Great. Thanks, Larry. So look, I think you heard in our prepared remarks, a lot of emphasis on kaizen, on lean culture, on cost initiatives. We're really proud of that. And I would say that that is the thing that has exceeded our expectations as we look at the bottom line throughout the year.
很好。謝謝你,Larry。我想你在我們事先準備的發言中也聽到了,我們非常強調改善(kaizen)、精實文化,以及各項成本措施。我們對此真的很自豪。而我會說,當我們檢視全年損益底線時,這一點的表現確實超出我們的預期。
We delivered 60 basis points of margin in the first half of the year against very low revenue growth. And in fact, we had a really good gross margin contribution year over year, 120 basis points in the first half of the year.
在上半年、在營收成長非常低的情況下,我們仍實現了 60 個基點的利潤率提升。事實上,我們的毛利率年對年貢獻也非常不錯,上半年提升了 120 個基點。
And in the second quarter, the formula that we've talked about historically is one that we really delivered on. We had roughly one point of positive impact in price exactly where we hope to be. And then notably, our variable cost productivity initiatives, and we talked a little bit about that, more than offset inflation.
而在第二季,我們過去一直談到的那套公式,我們確實做到了。價格帶來大約 1 個百分點的正向影響,正好符合我們希望達到的位置。此外值得注意的是,我們的變動成本生產力提升措施——我們也稍微談到一些——不僅抵銷了通膨,甚至還有餘裕。
And then you saw highlights from some of the G&A initiatives, really proud of the work that our IT team is undertaking. But some of those initiatives also contributed in the second quarter. So what happens in the back half of the year is more of the same.
接著你也看到一些管理費用(G&A)措施的亮點,我們對 IT 團隊正在推動的工作感到非常自豪。其中部分措施也在第二季有所貢獻。因此,下半年發生的事情會是同樣的延續。
In the third quarter, we'll see similar margin expansion to what we saw in Q2. And then in the fourth quarter, at the midpoint of the range, there is some tick up or uptick, I should say, in margin expansion. And it's going to come through continued price. Some of these productivity initiatives offsetting inflation and these cost initiatives that we've had success.
第三季,我們將看到與第二季類似的利潤率擴張。第四季,在區間中點來看,利潤率擴張會有一些小幅上升(uptick)。這將來自持續的價格因素。以及這些生產力提升措施抵銷通膨,還有我們已取得成效的成本措施。
And then I would also note that in the fourth quarter of last year, we had around 40 basis points of one-time R&D items we don't expect to repeat. So really, that's the contours of the year as we think about margin improvement. The one thing I would say is, at the beginning of the year, we were cautious, and we did risk adjust some of these productivity initiatives and some of these cost containment initiatives.
另外我也要指出,去年第四季我們有大約 40 個基點的一次性研發(R&D)項目,我們預期不會重演。所以,這就是我們在思考利潤率改善時,對全年輪廓的描述。我還想補充的是,年初時我們較為保守,並對部分生產力提升措施與成本控管措施做了風險調整。
So the question, how do you offset $500 million, it's real execution against these initiatives, delivering incremental profit versus our expectations. It's a company-wide effort. It's highlighted by things like kaizen. Initiative week that we had last week. But overall, I feel very good about the margin trajectory.
所以,關於如何抵銷 5 億美元的影響,答案在於對這些措施的確實執行,帶來超出我們預期的增量利潤。這是全公司共同努力的成果。也體現在像改善(kaizen)這樣的做法上。以及我們上週舉辦的倡議週(Initiative week)。但整體而言,我對利潤率走勢感到非常有信心。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
That's helpful. And Pete or Jay, I heard Pete, your comments about confidence in the medium-term goals. Any high-level thoughts right now in 2025? Do you expect some catch-up from China next year? And are you still confident in the mid-single digit growth outlook? Thank you.
這很有幫助。另外,Pete 或 Jay,我聽到 Pete 你提到對中期目標的信心。對於 2025 年,目前有沒有任何高層次的看法?你們是否預期明年中國會有一些回補?你們是否仍對中個位數成長的展望有信心?謝謝。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Larry. Thanks for the question. So as I mentioned in my closing comments that we feel confident in our midterm -- medium-term goals that we've laid out, both our revenue and our profit goals, profit, obviously, for the reasons that Jay laid out. And really, I would say on the growth side, we don't know what value China is going to create in 2025.
是的,Larry。謝謝你的問題。如我在結語中提到的,我們對已提出的中期——中期目標(medium-term goals)很有信心,包含營收與獲利目標;獲利部分當然如 Jay 所說有其原因。而在成長面,我會說,我們目前還不知道中國在 2025 年會帶來多大的價值。
Obviously, it's probably going to be more than we had previously expected. We'll have to see how that shakes out, and it's not time to give guidance on that, but that clearly will be a positive.
顯然,它可能會比我們先前預期的更多。我們得看後續如何發展;現在還不是提供相關指引的時候,但這無疑會是正向因素。
But it's less about markets in my mind. It's more about the core changes we've made in the company. Our commercial execution on large integrated deals, our capability to be able to sell more value, get price, be able to actually bring out new products that bring differentiated capabilities. I just feel good about the hand we're holding right now as we kind of finish this year out and move into not only just '25 but beyond.
但在我看來,重點不太在市場本身。更重要的是我們在公司內部所做的核心改變。我們在大型整合型交易上的商務執行力、我們能夠銷售更高價值、取得價格的能力,以及實際推出具差異化能力的新產品。當我們結束今年並邁入不只是 2025 年、而是更往後的期間時,我對我們目前手上的牌感到很有信心。
And again, just to make another comment relative to our Investor Day in November, it will be our first as an independent company. We want to really highlight the products that we've been building behind the scenes with this increased R&D investment.
另外,再補充一點關於我們 11 月的投資人日(Investor Day),那將是我們作為獨立公司後的第一次。我們希望能重點展示在增加研發投資後、我們在幕後打造的產品。
Remember, we've stepped up our percentage of R&D a couple of points over the last few years. And so in MR, in CT and PET/CT, in monitoring, in ultrasound, all of our business areas, we've been investing in the pharmaceutical diagnostic area, new molecules coming out. So we want to be able to tell that story.
請記得,過去幾年我們把研發占比提高了幾個百分點。因此在 MR、CT 與 PET/CT、監護(monitoring)、超音波等所有業務領域,我們也在藥物診斷領域投資,新的分子(molecules)正在推出。所以我們希望能把這個故事講清楚。
And so I feel good about the position that we're in. And we're, again, looking forward here to delivering on this -- our plans for the year and being in a well-positioned over the next couple of years to continue to grow the company.
因此,我對我們目前所處的位置感到很有信心。而我們也再次期待能在接下來把——我們今年的計畫落實到位,並在未來幾年保持良好態勢,持續推動公司成長。
Larry Biegelsen - Analyst
Larry Biegelsen - Analyst
Thanks a lot.
非常感謝。
Operator
Operator
Anthony Petrone, Mizuho Group.
Anthony Petrone,瑞穗集團。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
Thanks. Maybe two-part question here. One is going to be on orders and bookings, and then the second will be on Alzheimer's disease. So the order number, 3%-plus and book to bill, 1.06 times, comes in despite the headwinds in China. And I think a lot of that has to do with just state of the US market.
謝謝。我這裡可能有兩個部分的問題。第一個是訂單與接單(orders and bookings),第二個是阿茲海默症。所以,訂單數字成長 3% 以上、出貨比(book-to-bill)為 1.06 倍,即使面臨中國的逆風仍能達成。我認為其中很大一部分與美國市場的狀況有關。
So maybe just a little bit on the US market as it relates to funnel, specifically in the imaging and ultrasound segments. How much visibility is there? And can this feasibly extend into 2025?
所以,能否談談美國市場的情況,特別是與漏斗(funnel)相關的部分,聚焦在影像與超音波部門?目前能見度有多高?而這樣的態勢是否有可能延續到 2025 年?
And then for Alzheimer's disease, there's a couple of blood-based tests that had results out recently. Clearly, Vizamyl is at least in the early innings here, a preferred imaging solution to onboard Alzheimer's disease patients. So how does Alzheimer's disease play out from the PET/CT side when we consider new test potentially coming in? Thanks.
另外關於阿茲海默症,最近有幾項以血液為基礎的檢測(blood-based tests)公布了結果。很明顯,Vizamyl 至少在早期階段,是用於導入阿茲海默症患者(onboard Alzheimer's disease patients)的首選影像解決方案。因此,當我們考量可能會有新的檢測進入時,從 PET/CT 的角度來看,阿茲海默症的發展會如何演變?謝謝。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Maybe I'll start with that and then turn it over to Pete for some additional color on orders and the Alzheimer's question. Look, the 3% orders growth in the face of a decline in China, I thought it was a really good result. Orders excluding China were 6% and the book to bill, as you point out, actually the book to bill for the quarter of 1.06, I think, was the highest since we've spun off.
也許我先回答,然後再交給 Pete 補充一些關於訂單以及阿茲海默症問題的更多說明。你看,在中國下滑的情況下,訂單仍成長 3%,我認為這是非常好的結果。若排除中國,訂單成長為 6%;而如你所指出,本季的出貨比(book-to-bill)為 1.06,我認為這是我們分拆(spun off)以來最高的一次。
In the US, we had a very strong quarter. We saw strong orders and sales growth. And frankly, in each of the segments, orders growth outpaced sales growth in the US. So really, really nice market there.
在美國,我們這一季表現非常強勁。我們看到訂單強勁以及銷售成長。坦白說,在美國各個業務分部中,訂單成長都超過了銷售成長。所以那裡的市場真的、真的很不錯。
The market continues to be robust. We're seeing PDx putting very solid numbers up in line with procedure growth. As you know, we do a quarterly survey. And then we also do work looking at all of the surveys out there, in particular with respect to the US. And many of our customers are telling us in those surveys, they plan to spend more on capital investments in the second half.
市場持續強勁。我們看到 PDx 的數據非常亮眼,與手術量成長一致。如你所知,我們每季都會做一次調查。此外,我們也會針對市面上所有的調查進行研究,特別是與美國相關的部分。而在這些調查中,許多客戶告訴我們,他們計畫在下半年增加資本投資支出。
So I think that's a really good backdrop as we look to deliver on the guidance that we've just shared. We're seeing growth in the equipment market in the US And we also feel very good about the share position that we have. We launched a number of new products in ultrasound. And so we're seeing a real receptivity to some of the new products that we have in place.
因此,我認為這是我們在落實剛剛分享的財測指引時,一個非常好的大環境背景。我們看到美國設備市場在成長,同時我們也對自身的市占地位感到非常有信心。我們在超音波領域推出了多款新產品。因此,我們看到市場對我們已推出的一些新產品反應非常正面。
So overall, we feel quite good about the US market. We feel good about the orders backdrop. And then the other point I would note is backlog is up sequentially, $300 million in that range at $19 billion. So we're keeping the backlog at the level that we'd like to as we continue to grow the business. Pete, what would you add to that?
總體而言,我們對美國市場感覺相當不錯。我們對訂單的整體背景也感到樂觀。另外我想補充的是,積壓訂單(backlog)較前一季增加,約增加3億美元,達到190億美元左右。因此,在我們持續擴大業務的同時,也把積壓訂單維持在我們希望的水準。Pete,你會補充什麼嗎?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. No, I think you covered it, Jay, but we just -- I think a train in the US team just had a phenomenal quarter. And it is about products, but it is about -- we've talked about team itself, the talent upgrades that we put in place, the new sales disciplines and processes, and really our enterprise value proposition that we bring to a big IDN.
是的。不,我想你都涵蓋到了,Jay。不過我們——我認為美國團隊這一季表現真的非常出色。這當然與產品有關,但也與——我們談過團隊本身、我們所做的人才升級、新的銷售紀律與流程,以及我們帶給大型 IDN 的企業級價值主張有關。
We had quite a few larger wins. And again, I'd even site some new product areas like in the vascular lab area, where we're winning growth in the IGT business and taking share that we haven't realistically in previous years.
我們拿下了不少較大型的案子。而且我甚至會舉一些新的產品領域為例,例如在血管實驗室(vascular lab)領域,我們在 IGT 業務上贏得成長並取得市占,這是我們在過去幾年並未真正做到的。
But it's an older installed base in the United States. So we think we actually have a pretty good replacement cycle that's going to continue on. Signals from our customers, particularly CFOs, that we survey and such are positive about the investments.
但美國的已安裝基礎(installed base)相對老舊。因此我們認為,接下來其實會有一個相當不錯、且會持續的汰換週期。我們從客戶那裡得到的訊號——特別是我們調查的 CFO 等——對投資是正面的。
And the way this works out is when you see big growth in a lot of the med tech flowable businesses, catheters and such that are in the pharma side, ultimately, that puts more pressure to buy more equipment because you're putting more patients through the system. So we see that in delay coming through but are quite confident about how we see the US market.
而這個機制是這樣:當你看到許多醫療科技的耗材型業務(例如導管等,屬於藥品端)出現大幅成長時,最終會帶來購買更多設備的壓力,因為你讓更多病患進入醫療體系接受治療。所以我們看到這會在稍後反映出來,但我們對美國市場的看法相當有信心。
Anthony, your question on the radiopharmaceutical side, look, I think we're going to see a lot of different diagnostics pop up in many of these different phases. How well they'll be accepted and integrated into practice, I think, remains to be seen.
Anthony,關於你在放射性藥物(radiopharmaceutical)方面的問題,我想我們會在許多不同階段看到各式各樣的診斷工具出現。至於它們會被多好地接受並整合進臨床實務,我認為仍有待觀察。
As it relates to Alzheimer's specifically, I think all the baseline tests were done off of PET, pre, and the post being able to actually see where the amyloid beta is, actually see the elimination of it on scans, we believe is going to still be a hallmark of the products. And then again, depending on how well those therapies take off, most things, there will be lots of room for multiple products to continue to grow to do well.
就阿茲海默症而言,我認為所有的基線檢測都是以 PET 來做;而在治療前後能夠實際看到類澱粉β(amyloid beta)的位置,並在掃描上看到其被清除,我們相信仍將是這些產品的一個關鍵標誌。此外,取決於那些療法推進得多好,多數情況下,市場會有足夠空間讓多個產品持續成長並表現良好。
I would point though, back to this broader point about the CMS changes that just took place. Again, if you were doing scans and your radio -- your pharmaceutical product, again, in this case, the radiopharmaceutical diagnostic, you only receive maybe a few hundred dollars for reimbursement on it. And now you will receive something closer to the actual list price, which could be thousands of dollars, all of a sudden, the economics for a health care provider to move to that space makes a lot of sense.
不過我想回到剛剛提到的 CMS 近期變更這個更大的重點。同樣地,如果你在做掃描,而你的放射——你的藥品產品——在這個案例中是放射性藥物診斷產品——過去你可能只能拿到幾百美元的給付。而現在你將收到更接近實際牌價(list price)的給付,可能是數千美元;如此一來,醫療服務提供者轉向這個領域的經濟性就突然變得非常合理。
And if you have a larger distribution network of multiple molecules that you're bringing to that customer, you can contract that at a larger scale. And that's really what we're super excited about. Obviously, Alzheimer's being one part of that, but breast cancer, Parkinson's disease, cardiovascular disease down the road, all of those, we look and say, with some of these changes that have taken place, we're optimistic about what growth that can bring.
而如果你擁有更大的配送網路,能把多種分子(molecules)帶給同一位客戶,你就能以更大規模來簽訂合約。這正是我們非常興奮的地方。當然,阿茲海默症只是其中一部分;但乳癌、帕金森氏症、未來的心血管疾病等,我們都認為,隨著這些變更的發生,我們對其可能帶來的成長感到樂觀。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
Thank you.
謝謝。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Hi, guys. Good morning and thank you for taking my questions. Jay, my first question was on guidance. Revenues cut by 250 basis points. Operating margins tweaked up 10 basis points doesn't really explain the EPS, right? Any below the line assumptions change tax expense, other income?
嗨,各位。早安,謝謝你們回答我的問題。Jay,我的第一個問題是關於財測指引。營收下修250個基點。營業利益率上調10個基點,似乎無法解釋 EPS 的變化,對吧?線下(below the line)的假設是否有變動,例如稅費、其他收益?
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
No. I mean, broadly speaking, the below the line assumptions are unchanged. And so as we look at it, we have a revenue reduction. It's supported by what we've put forth.
沒有。我的意思是,整體而言,線下的假設沒有改變。因此從我們的角度來看,確實有營收下修。這也與我們所提出的內容相一致。
I think it is a fairly -- it continues to be a fairly wide EPS range, and a lot of that reflects the uncertainty that we see in China. So no major changes below the line, but -- and feel good about, in particular, given the strong performance in the first half, along with the continued line of sight to some of these additional productivity initiatives, we feel good about delivering on this range.
我認為 EPS 區間仍然相當寬,而其中很大一部分反映了我們在中國所看到的不確定性。所以線下沒有重大變動;而且——我們也有信心,特別是考量到上半年強勁的表現,以及我們對一些額外生產力提升措施仍有清晰的能見度,我們對達成這個區間感到有把握。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Understood. And Pete, one for you. I know you've spoken about new product momentum, NPI. You've talked about some of these new products that you're launching -- about to launch. I think you've had a bunch of software side as well. Maybe list them out. And what is incremental share as we look at back half into the medium term?
了解。Pete,我也有一題想問你。我知道你談過新產品動能、NPI。你也提到一些你們正在推出——或即將推出——的新產品。我想軟體端也有不少。能否把它們列舉一下?以及當我們看下半年到中期,市占的增量會是什麼?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. I think -- look, I think we've got -- across the business, we've had some multiple updates and upgrades across the product family line coming to value MR products that we've just introduced come out with a significant amount of upgrade product. I think one of the things that's driving a lot of growth, particularly in MR is our upgrades to our deep learning module in that case, the AIR Recon DL capability and installed base upgrades.
好的。我想——你看,我們在整個業務範圍內,針對產品家族線做了多次更新與升級;包括我們剛推出的高性價比 MR 產品,也帶來了相當多的升級產品。我認為推動許多成長的一個因素,特別是在 MR 方面,是我們對深度學習模組的升級——在這個案例中是 AIR Recon DL 的能力——以及對已安裝基礎的升級。
In the ultrasound space, particularly in general imaging, we introduced a quarter back quite a few new versions updated that product line, that has done quite well. This is the logic plant. So there's almost four different derivatives there, plus in our volumes in women's health care line. And we're seeing those pacing on track, if not better.
在超音波領域,特別是一般影像(general imaging),我們在上一季推出了不少新版本,更新了該產品線,表現相當不錯。這是 LOGIQ 平台。因此那裡幾乎有四種不同的衍生型號,另外在我們的婦女健康產品線也有相應的量。我們看到這些進展符合預期,甚至更好。
You might have seen our revenue in ultrasound was a little light in this particular quarter. But as we go into the second half, we expect that's going to pick up. In fact, our orders were positive. We had good orders pick up here. So that's a positive sign as we look forward.
你可能也注意到,我們這一季的超音波營收略顯疲弱。但進入下半年後,我們預期會回升。事實上,我們的訂單是正成長。我們的訂單回升得不錯。因此,展望未來,這是一個正面的訊號。
I mentioned vascular and IGT. We're doing quite well with our surgical C-arm OEC business. There's a bunch of new software applications, in-room capabilities that bring almost Cath Lab like capabilities into a mobile C-arm.
我提到了血管與 IGT。我們的外科用 C 臂 OEC 業務表現相當不錯。有一系列新的軟體應用、手術室內功能,幾乎能把類似心導管室(Cath Lab)的能力帶到行動式 C 臂上。
Our Allia platform, we're doing quite well with, which is growing share. And I'd say on the PDx side, particularly, on our monitoring systems that are in room, the new monitors themselves, weâre seeing some nice pickup. So thatâs the broader mix.
我們的 Allia 平台表現也相當不錯,市占率正在提升。我想在 PDx 端,特別是我們在室內的監護系統方面,新款監視器本身,我們看到不錯的拉貨動能。所以這就是更廣泛的產品組合。
And then what I was mentioning at Investor Day, weâll talk about what weâre going to see in the â25 through â27 range. Now how weâre thinking about where we are with photon counting, next-generation MRI, broader capabilities within PET/CT imaging, just to give an example. So those are some of the bigger investments, obviously, weâve been making for the past few years. And theyâre well on track, and again, will be a highlight of our Investor Day in November.
接著如同我在投資人日提到的,我們會談談在 2025 到 2027 年這段期間我們預期會看到什麼。也就是我們如何看待光子計數、下一代 MRI、以及 PET/CT 影像更廣泛的能力等,舉例來說。所以這些顯然是我們過去幾年一直在進行的一些較大型投資。而且進度非常順利,同樣也會是我們 11 月投資人日的重點。
Vijay Kumar - Analyst
Vijay Kumar - Analyst
Thatâs helpful. Thank you, guys.
這很有幫助。謝謝各位。
Operator
Operator
David Roman, Goldman Sachs.
高盛的 David Roman。
David Roman - Analyst
David Roman - Analyst
Thank you and good morning, everybody. I wanted to dig into China a little bit further. Understanding that the stimulus is a bit of an unknown, maybe we could just take a step back and you could talk a little bit about just underlying drivers in China because as you look at some of the third-party data, it looks like the vast majority of the installed base across ultrasound CT and MR has been refreshed in the past four years. So how should we think about the medium-term underlying growth in China? And is it more than just stimulus impacting the outlook here?
謝謝,大家早安。我想再更深入談一下中國。理解刺激方案仍有些不確定性,也許我們可以先退一步,請你談談中國的基本驅動因素;因為從一些第三方資料來看,超音波、CT 與 MR 的裝機基礎中,絕大多數在過去四年已經完成更新。那麼我們應該如何看待中國中期的基本成長?而這裡的展望是否不僅僅是刺激方案在影響?
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Yeah, David. Good question. As we look at China, Historically, we've seen this as a very robust growth market. Previously, at our Investor Day, we talked about China growth of 6% to 8%. And we feel good long term about the growth dynamics in China.
是的,David。好問題。我們看中國市場,歷來一直是非常強勁的成長市場。先前在投資人日,我們談到中國成長率為 6% 到 8%。而我們對中國長期的成長動能感到樂觀。
We had a very solid year last year with double-digit growth, and then we see a decline this year. But our decline this year is not related to age of installed base as we see it. Our decline this year is very much related to limited buying activity by hospitals as they await clarity on the stimulus.
去年我們表現非常扎實,達到兩位數成長,而今年我們看到下滑。但我們今年的下滑,依我們所見,並不是因為裝機基礎的年齡。我們今年的下滑主要是因為醫院在等待刺激方案更明確之前,採購活動有限。
As it pertains to your specific comment on age of installed base, the one thing I would note about your comment is that a lot of the recent purchases in the time frame that you referenced, and the refreshed equipment were at lower end or county hospitals versus major institutions where we have a higher presence.
針對你提到的裝機基礎年齡這點,我想補充的是:你所引用時間範圍內的許多近期採購與設備更新,更多發生在較低端或縣級醫院,而非我們滲透率較高的大型機構。
And so as we look at the age of our installed base in areas like ultrasound and imaging, it is above the numbers that you've described and is kind of consistent, broadly speaking, with global averages. So I do think there is a dynamic of the tier of hospital in play. But overall, we think this will continue to be a really nice market for us long term. Pete, I don't know if you'd add anything.
因此,當我們看我們在超音波與影像等領域的裝機基礎年齡時,它高於你所描述的數字,且大致上與全球平均一致。所以我確實認為醫院層級(tier)的差異是一個因素。但整體而言,我們認為長期來看這仍會是對我們非常好的市場。Pete,我不確定你是否要補充。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. I think you covered it, Jay, but just a couple of facts. As you know, David, the China population 1.4 billion, about 400 million have pretty good access. There's 1 billion people that don't. So we have a partnership with Sinopharm, with other broader distributor capabilities to be able to reach into that untapped market. And so that will continue to be a growth area. It's probably also going to be part of some of the investments that the government is making.
是的。Jay 你已經涵蓋到了,不過再補充幾個事實。如你所知,David,中國人口 14 億,大約 4 億人有相當好的醫療可近性。還有 10 億人沒有。因此我們與國藥(Sinopharm)合作,並結合更廣泛的經銷通路能力,得以觸及那個尚未開發的市場。所以那將持續是成長領域。這也很可能會是政府投資的一部分。
The other tidbit is that used equipment isn't actually allowed to be sold within China. And so there really isn't a recycling of used equipment around. It ends up being all new equipment coming in. And so that actually haven't has a higher effect on growth than in other markets where, particularly in the United States, where we have quite a bit of upgrades, and movement around equipment, that doesn't exist in China. So when we look at the numbers, I think we feel pretty good about what the longer-term growth potential is just based on those facts.
另外一個小重點是,中國其實不允許販售二手設備。因此並不存在二手設備的回收再流通。最後就會是全部導入新設備。而這對成長的影響其實比其他市場更大;特別是在美國,我們有相當多的升級與設備移轉,但在中國並不存在。所以當我們看這些數據時,基於這些事實,我們對長期成長潛力感到相當有信心。
David Roman - Analyst
David Roman - Analyst
That's super helpful. And maybe just a follow-up on some of your comments about the US. We've now heard a couple of companies talk about operating rooms and other parts of the hospital facing capacity constraints. You called out EP as an area of growth focus for you.
這非常有幫助。也許再追問一下你對美國的一些評論。我們現在聽到幾家公司提到手術室以及醫院其他部門面臨產能限制。你提到 EP 是你們的成長重點領域。
How should we think about your tethering to some of these higher growth attractive end markets for that structural heart or EP? Do we see that in your interventional imaging segment? So how should we think about the contribution to GE? And then does that change any of your strategic thoughts here from a business development standpoint on areas of interest being you sit around the periphery of a lot of these procedures going more into the implantable device or inside the body side of things?
我們應該如何看待你們與這些高成長、具吸引力的終端市場(例如結構性心臟或 EP)的連結程度?我們會在你們的介入影像(interventional imaging)部門看到這點嗎?所以我們應該如何看待對 GE 的貢獻?另外,從業務發展的角度,當你們位於許多這類手術的周邊,是否會改變你們的策略思考,例如更深入到植入式裝置或體內端的領域?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, David. It's a really good question. And obviously, we'll spend more time in some strategic settings on this. But look, at a high level, we have the strategy we focus on -- we articulated D3, which, again, is smart integrated connected devices that work together around a given disease state or care pathway and enable to drive more productivity or better outcomes with digital AI features.
是的,David。這是個非常好的問題。而且很明顯地,我們會在一些策略場合花更多時間討論。但總體來說,我們有一個聚焦的策略——我們闡述了 D3,也就是智慧、整合、互聯的裝置,能圍繞特定疾病狀態或照護路徑協同運作,並透過數位與 AI 功能來提升生產力或改善結果。
And so if you take that EP example you had, the first part is having world class electrophysiology labs that we can win the hardware. And the reality of it is, a few years ago, we probably didn't have all the right features. We do now. So we think from a standpoint of winning those labs, we're going to win at a higher rate than we did in the past.
所以以你提到的 EP 為例,第一部分是擁有世界級的電生理實驗室(EP labs),讓我們能在硬體上勝出。事實上,幾年前我們可能還沒有所有正確的功能。但現在我們有了。因此我們認為,從贏得這些實驗室的角度來看,我們的勝率會比過去更高。
On the disease stage side of electrophysiology itself, we actually have folks that are primarily focused on that to say, how does ultrasound, how does the EP devices, how does the actual data systems work together so we can come up with a better solution. And we are working on that. It's one of the main reasons that we created the IGT ultrasound alignment because there's a lot more cardiovascular benefits in everything from channel to the development side.
在電生理本身的疾病階段(disease stage)面向,我們其實有團隊專注於此,去思考超音波、EP 裝置以及實際的資料系統如何協同運作,讓我們能提出更好的解決方案。而我們正在推進這件事。這也是我們建立 IGT 與超音波對齊(alignment)的主要原因之一,因為從通路到研發端,各方面都有更多心血管方面的效益。
And to your broader point, when you start thinking about disease states, it opens your lens up to say, well, should I partner with this company more because if we do, we could solve this customer problem or should I buy this asset because together, these four things create more value? And to answer your question, absolutely, weâre expanding our horizons to think about what should be part of GE HealthCare.
而就你更宏觀的觀點而言,當你開始以疾病狀態來思考時,你的視角會被打開:例如,我是否應該與某家公司更深入合作,因為這樣我們就能解決某個客戶問題;或我是否應該收購某項資產,因為把這四件事結合起來能創造更大價值?回答你的問題:絕對是的,我們正在擴大視野,思考哪些應該成為 GE HealthCare 的一部分。
David Roman - Analyst
David Roman - Analyst
Terrific. Thanks so much and look forward to seeing you in November.
太好了。非常感謝,也期待 11 月見到你們。
Operator
Operator
Matt Taylor, Jefferies.
Jefferies 的 Matt Taylor。
Matt Taylor - Analyst
Matt Taylor - Analyst
Hi. Thank you for taking the question. I had one question on the PDx business. You talked a little bit about the Medicare changes, obviously, a big positive for that space. I was wondering if that changes your thoughts on the long-term opportunity or the growth rate for the contrast media molecular imaging markets that you're in? And I was hoping -- you've called out Vizamyl a couple of times. The last few calls with the great growth you're seeing there. If you could outline the opportunity for that or for flurpiridaz just to give us a better sense of what they're contributing today or how you feel about them contributing to growth, especially next year as you launch flurpiridaz?
嗨。謝謝讓我提問。我有一個關於 PDx 業務的問題。你們稍微談到 Medicare 的變動,顯然對這個領域是很大的利多。我想請問,這是否改變你們對於所處的對比劑分子影像市場長期機會或成長率的看法?另外我也希望——你們已經提到 Vizamyl 幾次了。在最近幾次電話會議中,你們看到那邊有很好的成長。能否概述一下它的機會,或是 flurpiridaz 的機會,讓我們更清楚它們目前的貢獻,或你們認為它們對成長的貢獻會是如何,尤其是明年你們推出 flurpiridaz 時?
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Sure. Maybe I'll start with a few comments and then turn it over to Pete as well. Overall, the PDx business has been growing really well. We saw 14% in the second quarter. A lot of that relates to volume. About 10% of that relates to volume, with a couple of points of price and new products also contributing.
當然。也許我先講幾點,然後也交給 Pete 補充。整體而言,PDx 業務成長得非常好。我們在第二季看到 14% 的成長。其中很大一部分與量有關。大約 10% 來自量的成長,另外也有幾個百分點來自價格與新產品的貢獻。
And you heard us talk about some of the new specialty products in the call. We talked about Vizamyl volumes tripling in the US. And based on the new CMS along with the new approval, we're really optimistic about this particular product long-term.
你們也聽到我們在電話會議中談到一些新的專科產品。我們提到 Vizamyl 在美國的用量成長到三倍。而基於新的 CMS 規定以及新的核准,我們對這個產品的長期前景非常樂觀。
And if I think about areas that are changing relative to the prior Investor Day and prior investor -- our long-term expectations, this whole area is one that we have a little bit more optimism on. Vizamyl sales at this point are still very small. So we're still talking a few million dollars. But as we see the uptake of the Alzheimer's therapies, we're seeing continued interest and implementation of programs to support diagnostics in this area.
如果我去想相較於先前投資人日以及先前投資人——我們的長期預期——有哪些正在改變的領域,這整個領域是我們更為樂觀的一塊。Vizamyl 目前的銷售額仍然非常小。所以我們談的仍是幾百萬美元的規模。但隨著阿茲海默症療法的採用增加,我們看到市場對於支持此領域診斷的方案持續有興趣並加速落地。
So we expect to see continued growth throughout the year. I think the CMS ruling could unlock accelerated growth next year, both in Vizamyl, flurpiridaz and some of the other products that we're working on. Pete, I don't know if you'd like to add to that.
因此我們預期全年將持續成長。我認為 CMS 的裁定可能在明年解鎖加速成長,涵蓋 Vizamyl、flurpiridaz 以及我們正在推進的其他一些產品。Pete,不知道你是否想補充?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. I just think, we haven't framed up what all the longer-term growth yet will be on the molecules. But needless to say, we're more optimistic today than we were prior to the approval. And again, we're working through right now and frame this up is just take an example, again, of a product that the hospital might be paying a couple of thousand dollars for, but they're getting reimbursed $200 for.
是的。我想我們還沒有把分子產品長期成長會是什麼樣子完整地框架化。但不用說,相較於核准之前,我們今天更為樂觀。而且我們現在正在做的、要把它框架化的方式,是舉個例子:某個產品醫院可能要付出幾千美元,但他們只能拿到 200 美元的給付。
Now, in the future, they'll get reimbursed at what they're paying for it. And so to be able to detail that and have a discussion with an institution about how to build out a program that's actually going to be a value creator for them. And our confidence that the outcome capabilities for the patient is higher is very strong.
未來,他們將會以其支付的成本水準獲得給付。因此我們就能把這點講清楚,並與機構討論如何建立一個對他們而言實際能創造價值的計畫。而我們對於提升病患結局能力的信心非常強。
So if you think about Cerianna for metastatic breast cancer, it's actually on many of the guidance documents now, but it's challenging economical for someone to actually implement it on a day-to-day process. On tomorrow situation, that changes.
所以如果你想到用於轉移性乳癌的 Cerianna,它其實已經被納入許多指引文件,但要在日常流程中落地執行,在經濟性上是有挑戰的。在明天的情境下,這會改變。
And the other aspect is probably even less about what we do on diagnostics and more about what pharmaceutical companies are doing with therapies. And so the more therapies that come out in the space, the more you need someone like a GE HealthCare that has the equipment, the data integration, the distribution capabilities and the diagnostic molecules to help solve the equation.
另外一個面向,可能甚至較少是關於我們在診斷上做什麼,而更多是關於藥廠在治療上做什麼。因此,這個領域推出的療法越多,你就越需要像 GE HealthCare 這樣的公司,具備設備、資料整合、配送能力以及診斷分子,來協助解這道方程式。
And so, we will obviously spend more time on this with investors, but this is a very positive direction. And it's quite helpful for our growth strategies in the coming years.
因此,我們顯然會花更多時間與投資人討論這一塊,但這是一個非常正向的方向。而且對我們未來幾年的成長策略相當有幫助。
Matt Taylor - Analyst
Matt Taylor - Analyst
Thanks, guys. Can I just ask one follow-up to on China? I'm just trying to square your comments with some of the competitors, the peers, and your approach to guidance there. Do you think that your -- seeing the same things as your competitors are talking about -- they're talking about orders starting to come back through the second half of the year. And I'm just curious if you're being more purposeful about being conservative with your China guidance just given the uncertainty there or do you think that you're aligned with how others are calling it?
謝謝各位。我可以再追問一個關於中國的問題嗎?我只是想把你們的評論與一些競爭對手、同業以及你們對指引的做法對照起來。你們是否認為你們——看到的情況與競爭對手所談的是一樣的——他們在談下半年訂單開始回流。我想了解的是,你們是否因為那邊的不確定性而更刻意地在中國指引上採取保守,還是你們覺得你們的看法與其他人一致?
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Sure. So just to start, and I'll turn it over to Pete. First half decline in sales, 15%. As we look at the market and the orders in the market, and we're talking about market and tender activity versus anything share related, we think a prudent number is in this -- adjust down the number $500 million at the midpoint, leading to high-teens decline in the second half of the year.
當然。我先說一下,然後交給 Pete。上半年銷售下滑 15%。當我們看市場以及市場中的訂單——我們談的是市場與招標活動,而不是任何市占相關——我們認為較審慎的數字是在中點下調 5 億美元,導致下半年出現高十幾%的下滑。
Now again, we've taken out the benefit of impact from stimulus on sales. And I would also say that through at least the third quarter, we have a very locked-up dynamic on orders and into the fourth.
再說一次,我們已經把刺激方案對銷售的影響所帶來的好處排除在外。我也會說,至少到第三季,我們在訂單上有非常「鎖定」的態勢,並延續到第四季。
Now, could we be wrong to the upside? We might be. But as we look at it today, we felt it was prudent not to try to time the impact on the fourth quarter in terms of sales, and we've removed that.
那麼,我們有可能低估、結果向上嗎?有可能。但以我們今天的判斷,我們認為不應嘗試去抓第四季刺激影響在銷售端的時點,因此我們把那部分拿掉了。
I'm hopeful that we do better. But at this point, we think this was the right thing to do. We'll watch the stimulus really carefully as we think about what the impact on to 2025 will be. But we have continued declines in a tough market forecasted. And again, it's not a GE specific item. This is a broad-based market view that we have.
我希望我們表現能更好。但就目前而言,我們認為這樣做是正確的。我們會非常仔細地觀察刺激方案,並思考它對 2025 年的影響。但我們的預測是在艱困市場中持續下滑。而且再說一次,這不是 GE 特有的問題。這是我們對整體市場的廣泛性看法。
Matt Taylor - Analyst
Matt Taylor - Analyst
All right. Helpful color.
好的。這些補充很有幫助。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
I think Jay hit the point. So again, when this comes back, for us, this is really largely related to timing of the China stimulus program. So we're not betting on the timing. We think we've got our base case lined out well, which is really tied to our installed base, what's our secured business that we have here coming through the second half.
我想 Jay 已經點出重點了。所以再說一次,當它回來時,對我們而言,這主要與中國刺激方案的時點有關。所以我們不去押注時點。我們認為我們已把基本情境規劃得很清楚,主要是連結到我們的裝機基礎、以及我們在下半年已經掌握的既有業務會如何進來。
And as I mentioned, we would expect to see some orders uptick later this year. But when we take a look at particularly the equipment, we have between the time you win a tender, get an order, have the room ready and install it, that order to sales piece would be very tight. And hence, why we just decided to take it out.
如我提到的,我們預期今年稍晚會看到一些訂單回升。但當我們特別看設備端,從你贏得招標、取得訂單、把機房準備好到完成安裝,這段從訂單到認列銷售的時間會非常緊。因此我們才決定把它排除。
Operator
Operator
Graham Doyle with UBS.
UBS 的 Graham Doyle。
Graham Doyle - Analyst
Graham Doyle - Analyst
Good morning, guys. Thanks for taking the question. I got a follow-up on China. So just when -- Jay, you kindly called out the actual number. It looks to me like there's like 40% down in H2 versus your original assumption, which is obviously a very, very large change. And I just wonder what's the confidence then that you do with your midterm targets so starting from next year, given how volatile that market is?
各位早安。謝謝讓我提問。我有一個關於中國的追問。所以——Jay,你很貼心地點出了實際數字。在我看來,下半年相較於你們原先的假設大概下滑了 40%,這顯然是非常、非常大的變動。我想問的是,鑑於那個市場波動這麼大,那麼你們對中期目標(從明年開始)達成的信心如何?
And to the point Matt made, I was with both Siemens and Philips today. And it does sound like they're not forecasting a decline of anywhere near that magnitude in the second half in China revenue. So is it genuinely just a lot more prudence or is there something happening in, say, the patient monitoring market that maybe the others are seeing? It would be great to get that color. Thank you.
回到 Matt 提到的重點,我今天也和西門子(Siemens)以及飛利浦(Philips)都聊過。聽起來他們並沒有預測中國營收在下半年會出現接近那種幅度的下滑。所以這真的是單純更保守審慎,還是說例如在病患監護市場上,可能有其他人看到一些正在發生的事情?如果能提供一些背景說明會很有幫助。謝謝。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah, Graham. I know I can start. Look, for our business in China, it's primarily an imaging ultrasound story. All of us have different mixes of products. So there's not obviously a one-to-one match. But I'll tell you what we did.
是的,Graham。我想我可以先說。你看,我們在中國的業務主要是影像與超音波的故事。我們每家公司產品組合都不一樣。所以顯然不會是一對一完全可比。但我可以告訴你我們做了什麼。
So what we've done is, we have our sales force pulling out to all 31 of the provinces, all of our big customers and actually asking the questions, when you're going to buy, what you're going to buy, what that's going to look up, and we roll that all up for each 31 Providence and try to understand from what they're saying, what the timing would look like.
我們做的是,讓我們的銷售團隊走訪全部 31 個省份、所有主要客戶,實際去問幾個問題:你什麼時候要買、要買什麼、看起來會是什麼樣子,然後把這些資訊按 31 個省份彙總起來,並試著從他們的說法中理解時程會長什麼樣。
And then based on that, understand how long it takes a tender, how long it takes to get to order, how much time then to actually do an install based on the mix. And when we do that rollout, we do think there's going to be orders coming but we just don't think that there's enough time on the clock from a sales standpoint. And to Jay's point, we might be wrong, but we're not in the business of trying to guess, and we just thought it prudent to take it out.
接著基於這些資訊,去理解一個招標需要多久、從招標到下單需要多久、再到依產品組合實際完成安裝又需要多少時間。當我們把這些推演做完後,我們確實認為訂單會來,但我們只是覺得從銷售端來看,時間不夠。而且如 Jay 所說,我們可能會判斷錯,但我們不做猜測的生意,所以我們認為把它拿掉是審慎之舉。
Graham Doyle - Analyst
Graham Doyle - Analyst
Okay. Just to the context of the question, why was it in there in the first place? At what point did you put stimulus into the guidance? At the start of this year, was it Q1 because it didn't seem like something that was that not certain to start. So I'm just trying to figure out how much more (multiple speakers) will you have taken down?
好的。就問題的脈絡來說,為什麼一開始會把它放進去?你們是在什麼時點把刺激措施納入財測指引的?是今年一開始嗎?是 Q1 嗎?因為一開始看起來並不是那麼確定的事情。所以我只是想弄清楚,你們到底下修了多少(多位發言者)?
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. Look, a very fair question. And keep in mind, in O2, when the stimulus came within four to six months, it ramped unbelievably quickly. And so I think as we started the year, it wasn't super clear what -- if there was going to be stimulus or not, I think you may recall. But as we got closer to Q2, the question is, if it follows the same ramp, it's going to probably be within this year.
是的。你看,這是個非常合理的問題。而且請記得,在 O2 的時候,刺激措施在四到六個月內就到位,拉升速度快得驚人。所以我想在今年年初時,其實並不非常清楚到底會不會有刺激措施,你可能也記得。但當我們更接近 Q2 時,問題變成:如果它沿著同樣的爬坡速度,那很可能會在今年之內發生。
What's new is the fact that when it is slower and someone's deciding to buy, if you buy something now, you may not get the 30%, 40%, 50% value from the government to actually support your sale. So naturally, you're going to wait to make a decision to see what stimulus is. That's really the difference here in the calculation that I don't think anybody saw that would take that much longer.
新的變化在於:當進度變慢、而有人正在決定是否要買時,如果你現在買,你可能拿不到政府用來支持你這筆銷售的 30%、40%、50% 補助價值。所以很自然地,你會等到看清楚刺激措施是什麼再做決定。這才是這次計算上的差異;我想沒有人預料到會因此拖得這麼久。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
I mean the only thing to add is, this is not even like so, we're seeing a depressed level of demand relative to normal as people await clarity. We think the stimulus is a good positive thing long term. But in the market, as we saw it in Q2, as we see Q3 quarter to date, it is depressing activity in the market thus far. And so that's why we made the assumption that we did.
我想唯一要補充的是,這甚至不是說——我們看到相較於正常水準的需求被壓抑,因為大家在等待更明確的訊息。我們認為刺激措施長期來看是正面的好事。但就市場而言,從我們在 Q2 看到的、以及目前 Q3 迄今看到的,它確實到目前為止正在壓抑市場活動。所以這就是我們做出那個假設的原因。
Operator
Operator
Patrick Wood, Morgan Stanley.
摩根士丹利(Morgan Stanley)的 Patrick Wood。
Patrick Wood - Analyst
Patrick Wood - Analyst
Brilliant. Thank you so much taking the questions. Apologies, if I heard this wrong. I thought you guys mentioned that Q3 was something like plus 1% organic. And so, of the implied Q4 step-up, qualitatively, how much is a function of those ultrasound launches relative to the strong US imaging market? Apologies if I missed this earlier, but if you could just unpack the 4Q, that would be really helpful.
太好了。非常感謝讓我提問。如果我聽錯了先道歉。我以為你們提到 Q3 的有機成長大概是 +1% 左右。因此,對於隱含的 Q4 躍升,從質性角度來看,有多少是來自那些超音波新品上市,相對於美國強勁的影像市場?如果我前面漏聽了也抱歉,但如果你們能把 4Q 拆解說明一下,會非常有幫助。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Sure. A lot of this comes down to the strong order performance that we saw in the second quarter and when we booked that for delivery in Q3, Q4 for the ex-China business. Maybe taking a step back and talking about revenue confidence generally. Patrick, about 45% of our revenue is recurring revenue, either in the form of services or PDx. And I would say the volatility around these categories is reasonably low. We have decent predictability.
當然。這很大一部分取決於我們在第二季看到的強勁訂單表現,以及我們把這些訂單安排在 Q3、Q4 交付(中國以外業務)。也許先退一步,談談我們對營收信心的整體來源。Patrick,我們大約 45% 的營收是經常性收入,形式包括服務或 PDx。我會說這些類別的波動性相對低。我們有不錯的可預測性。
Now the remaining 55% is equipment. And so for us, as we think about equipment, one of the things we look at is the security rate, which is the equipment that we have in the backlog that's scheduled for a given quarter.
剩下的 55% 是設備。所以對我們來說,在看設備時,我們會看一個指標叫做「已鎖定比率」(secured rate),也就是我們在積壓訂單中、已排定在某一季度交付的設備占比。
Over the last four quarters, we had around 75% of our revenue in this secured rate coming from the backlog, with the other 25% sold and installed in the quarter, so really 25% of the equipment is up for grabs in a given quarter, that's a phenomenon, again, that we see generally speaking in each of the quarters.
過去四個季度,我們大約有 75% 的營收是由這個已鎖定比率、也就是來自積壓訂單所貢獻;另外 25% 則是在當季銷售並完成安裝。也就是說,在任何一個季度,真正「可爭取」的設備大約是 25%;這個現象基本上每一季都差不多。
As we look at the second half of the year, we see this similar, if not slightly better than the historic 75%-25% split going into the second half. And so really, what the Q4 step-up, there's a normal step-up from Q3 to Q4. But in specific as it relates to why we have this high level of confidence, it comes down to the backlog and when we're expecting those deliveries to take place.
展望下半年,我們看到的情況與歷史上的 75%/25% 拆分相近,甚至可能略好一些。因此,所謂 Q4 的躍升,一部分是從 Q3 到 Q4 本來就會有的正常躍升。但更具體地說,為什麼我們有這麼高的信心,關鍵在於積壓訂單,以及我們預期這些交付會在什麼時點發生。
So really, that's the driver around the step-up. Of course, to your point, we're going to see continued performance on some of the new product launches. We're also expecting to see continued robust performance out of the US market. But again, the analytics that we have really supports this Q4 step-up, which we feel good about.
所以,這才是推動躍升的主要因素。當然,如你所說,我們也會看到部分新品上市帶來的持續表現。我們也預期美國市場會持續有強勁表現。但再次強調,我們的分析確實支持這個 Q4 的躍升,我們對此感覺良好。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
I think the other point you touched on it, Jay. With some of the share gains we've had on some of the larger equipment a year ago, we actually have now service contracts growth. And we're expecting our service contract growth during the second half, not just expecting we can see it. It's already on the books. We'll step up a few points in the second half, and that has a higher margin. And obviously, it's already on the books.
我想你也提到了另一點,Jay。由於我們在一年前在一些大型設備上取得了市占提升,現在其實帶動了服務合約的成長。而且我們預期下半年的服務合約成長——不只是預期,我們看得到。它已經在帳上了。下半年會提升幾個百分點,而那部分毛利率更高。而且顯然,它已經在帳上了。
Patrick Wood - Analyst
Patrick Wood - Analyst
Yeah. Good point on the warranty role. Very one quick follow-up. It's been a few years since I ran this math, but the US installed base, last time I tried to back it out. I got the average age, it's something like seven years, so pretty old. I don't know if you have any instinct on how that number hits here.
是的。關於保固轉換(warranty roll)的點很好。再追問一個很快的問題。我已經好幾年沒算這個數了,但美國的裝機基礎(installed base),我上次試著回推時,算出平均機齡大概是七年左右,算是蠻老的。我不知道你們對這個數字在這裡的影響有沒有什麼直覺。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Yeah. I think it obviously varies quite a bit by modality. It varies by company too, based on -- if you're taking a look at your own installed base or the overall, I think, in average, it's a little bit older than that. We have some modalities, particularly in MR, where it's probably even a few years older than that.
是的。我想這顯然會因不同的成像模態而差異很大。也會因公司而異,取決於——你是在看自家裝機基礎,還是看整體市場;我認為平均來說,可能比那個還要更老一些。我們有一些模態,特別是 MR(磁振造影),可能甚至還要再老幾年。
And so that's really boding well right now for us doing upgrades and stuff on conversion. But we believe, when we take a look at the whole of ours plus the installed base, there's actually a reasonable amount of replacement cycle needed because of the age.
因此,這對我們目前在轉換方面進行升級等工作而言,確實是個很好的跡象。但我們相信,當我們檢視我們自身加上既有裝機基礎的整體情況時,因為設備年齡的關係,實際上需要進行汰換週期的量是相當合理的。
Patrick Wood - Analyst
Patrick Wood - Analyst
Brilliant. Thank you.
太棒了。謝謝你。
Operator
Operator
Suraj Kalia, Oppenheimer & Company.
Suraj Kalia,Oppenheimer & Company。
Suraj Kalia - Analyst
Suraj Kalia - Analyst
Yeah. So thank you for taking my questions. And Peter, I'll throw both of them, you guys this way. And both of these questions are designed really for assessing the differential impact.
是的。謝謝你回答我的問題。Peter,我把這兩個問題都丟給你們。這兩個問題主要都是為了評估差異化影響。
So first on China, Peter, I wanted to piggyback on David's question from earlier. Your competitors are talking about value partnerships, local for local. Maybe set the stage, when China opens up right. Will the rising tide lift everyone equally or do you think there will be a differential impact?
首先談中國,Peter,我想延伸先前 David 的問題。你們的競爭對手在談價值型合作夥伴關係、在地為在地(local for local)。也許先鋪陳一下,當中國重新開放時。水漲是否會船高、讓所有人同等受益?還是你認為會有差異化影響?
And part of me is also thinking, how is the book to build specifically within China, looking for the different people? And how should we think about when China opens up, what is the differential impact? Peter, that's one question. And I'll throw the second one also quickly your way.
我也在想的是,在中國境內,特別是 book-to-build(接單/出貨比)對不同業者的表現如何?以及我們應該如何看待中國開放時的差異化影響?Peter,這是第一個問題。我也很快把第二個問題一併丟給你。
Radiopharmaceuticals, again, your competitors are talking about pharmacy networks that give them an edge in radiopharmaceuticals. Help us understand GE's buffers for growth in the segment, especially given what Medicare is doing? Thank you for taking my question.
放射性藥物方面,同樣地,你們的競爭對手在談藥局網路,認為這讓他們在放射性藥物上更具優勢。請協助我們理解 GE 在這個領域的成長緩衝/支撐因素,特別是在 Medicare 目前作法的背景下?謝謝你回答我的問題。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Sure. I would say, look, on China, I don't know if I have any better crystal ball than anyone else. I think we are making the assumption that a rising China will benefit everyone at some level.
當然。我會說,關於中國,我不確定我是否比其他人有更準的水晶球。我想我們的假設是,中國走強在某種程度上會讓所有人受益。
Obviously, there's a lot of local competition. Thereâre multinational players. I think everybody will play at a different point. We've been manufacturing for over 35 years, we source locally for the in-China market. And so we believe we can compete just like a local company.
顯然,當地競爭很多。也有跨國玩家。我想每個人會在不同的定位點上競爭。我們製造已超過 35 年,針對中國市場在地採購。因此我們相信我們能像本地公司一樣競爭。
And we're very focused on, as you move into the non-postal cities into the west areas that you need to actually be even more of a value-based product and capabilities. And so there's two sides that's very high end and also value. And I think we've got the type of lineup that we can be competitive there. But I don't think I have any better insights relative to that on how China will play out. Jay, I don't know if you want to add any comments there.
而且我們非常聚焦於,當你從一線城市往非一線城市、往西部地區移動時,你實際上需要更偏價值導向的產品與能力。因此有兩個面向:非常高端,以及價值型。我認為我們具備的產品組合能在那裡保持競爭力。但我不認為我在中國將如何發展這件事上,能提供更好的洞見。Jay,我不知道你是否想補充一些看法。
James Saccaro - Chief Financial Officer, Vice President
James Saccaro - Chief Financial Officer, Vice President
Sure. I think we'll watch it over time, but we feel very good about the share position that we've been able to protect over time. And a lot of that comes down to the manufacturing that we do in China, for China, the large teams that we have on the ground that Pete described. So from a share standpoint, we've been fairly effective thus far.
當然。我想我們會隨時間觀察,但我們對於我們長期以來能夠守住的市占位置感到非常有信心。其中很大一部分來自我們在中國、為中國所做的製造,以及 Pete 所描述我們在當地的大型團隊。因此就市占角度而言,到目前為止我們一直相當有效。
And so as we look at the next stimulus, we have all reasons to believe we'll be able to participate in that market going forward. And we're designing plans to execute on that.
因此當我們展望下一輪刺激措施時,我們有充分理由相信未來能夠參與該市場。而我們也正在制定計畫以落實執行。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
So if we switch to your question relative to radiopharmaceuticals. And look, our -- we'll spend again more time on this at our Investor Day. But again, if you think about what makes us unique, everything from cyclotrons and capabilities for on-site generation of your own isotopes at an institution, we're one of the very few companies that has that as well as the PET technology and PET/CT, PET/MR.
接著切換到你關於放射性藥物的問題。我們會在投資人日再花更多時間談這個。但如果你想想是什麼讓我們獨特,從迴旋加速器(cyclotrons)到在機構內現場生成自有同位素的能力,我們是少數同時具備這些能力的公司之一,並且也擁有 PET 技術以及 PET/CT、PET/MR。
And actually in the spec camera world becomes super important and multi-head -- 10-plus head system that allows you to do some of these oncology staging drugs. And again, if you don't have that, that part of the exam could be 1.5 hours, where on our system, it's 15 minutes. So there's phases of that.
而且其實在 SPECT 相機領域也變得非常重要,包含多探頭——10 個以上探頭的系統,讓你能做某些腫瘤分期用藥的檢查。再者,如果你沒有那樣的系統,那部分檢查可能要 1.5 小時;而在我們的系統上只要 15 分鐘。所以這裡面有不同階段的價值。
Network, we do have a distribution structure. There are some other players that have a much larger distribution structure. I would argue with the CMS change, the real value here isn't if you can distribute it, it's this do you actually make it.
至於網路,我們確實有配送架構。也有一些其他玩家擁有更大的配送架構。但我會主張,隨著 CMS 的變更,這裡真正的價值不在於你能不能配送,而在於你是否真的能製造。
And so we actually make these molecules that are in some ways is going to be transformational relative to diagnosis of certain diseases. And you could argue they've been handicapped because they haven't been given their fair share of reimbursement for the value they create.
因此我們實際上在製造這些分子,某種程度上將對特定疾病的診斷帶來變革性影響。你也可以說,它們一直受到限制,因為它們沒有因其創造的價值而獲得公平的給付補償。
It's a preliminary rule. We believe that's going to come into effect on January 1. If it does, we do think that you're going to definitely see significantly more growth on these molecules than we had estimated they would be being treated as a supply. So more to come. And obviously, that gives us more energy to say this is a space to invest and obviously, continue to build out on. Thanks for your question.
這是一項初步規則。我們相信它將在 1 月 1 日生效。如果真的生效,我們確實認為,這些分子的成長將明顯高於我們原先的估計——原本它們被當作供應品(supply)來對待。後續還會有更多資訊。而且顯然,這也讓我們更有動力認為這是一個值得投資、並持續擴建的領域。謝謝你的提問。
Operator
Operator
Thank you. And this concludes the Q&A session. Please proceed with any closing remarks.
謝謝。問答環節到此結束。請進行任何結語。
Peter Arduini - President, Chief Executive Officer, Director
Peter Arduini - President, Chief Executive Officer, Director
Thank you, everyone for joining us today. And we look forward to connecting with you in the coming days at one of our conferences in the next few months. As a reminder, we'll host our Investor Day in New York on November 21. Thanks so much for listening.
謝謝各位今天加入我們。我們期待在接下來幾天、以及未來幾個月於我們其中一場會議上與各位交流。提醒一下,我們將於 11 月 21 日在紐約舉辦投資人日。非常感謝各位收聽。
Operator
Operator
And thank you all who participated in today's conference, and you may now disconnect.
也謝謝所有參與今天會議的各位,現在您可以斷線。